A trial team from Wilson Sonsini Goodrich & Rosati delivered a $1 billion save for client Amphastar Pharmaceuticals Inc. after a federal jury in Boston on Friday sided with the company in a patent fight over its generic version of the blood-thinner Lovenox.

Wilson Sonsini partners Michael Sommer and Doug Carsten led Amphastar's team, squaring off against Momenta Pharmaceuticals Inc., represented by Choate, Hall & Stewart, and Novartis AG's Sandoz unit, represented by Morrison & Foerster.

After a nine-day trial, the jury deliberated for a day before finding that Amphastar infringed Momenta's patent, but that the patent was invalid based on lack of enablement and lack of written description. (i.e. that the patent did not describe the invention “in such full, clear, concise, and exact terms as to enable any person skilled in the art…to make and use the same.”)